37 results

• JAK Inhibitors Could Increase Cancer Risks by as Much as 40%: Study

  July 3, 2025

  Irvin Jackson

  A new study reinforces previous concerns that arthritis and autoimmune disease treatments like Xeljanz may be linked to an increased risk of cancer.

• Xeljanz Side Effects May Cause Weight Gain: Study

  May 22, 2025

  Irvin Jackson

  A new study finds that Xeljanz use can lead to a 5% or more increase in weight in the first three months of use, which could continue throughout the first year.

• Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study

  November 8, 2023

  Martha Garcia

  A new study links Xeljanz, Rinvoq and similar drugs to an increased risk of developing acne.

• Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors

  May 1, 2023

  Russell Maas

• Drugs Advertised on TV Often Have Low Therapeutic Value, Study Finds

  January 26, 2023

  Irvin Jackson

  Harvard researchers warn that drug companies spend billions of dollars advertising medications which are not as effective, and often more expensive, than other options, researchers warn.

• EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks

  November 4, 2022

  Irvin Jackson

  European regulators urge doctors to limit the use of Xeljanz and similar drugs among certain patients more prone to heart problems and blood clots.

• Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks

  September 8, 2022

  Irvin Jackson

  A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.

• Xeljanz Infection Risk Higher Than TNF Inhibitors: Study

  August 15, 2022

  Irvin Jackson

  Xeljanz use carries a higher infection risk than other arthritis drugs, like Humira, according to the findings of a new study.

• Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study

  May 18, 2022

  Irvin Jackson

  A new study links Xeljanz and similar drugs to an increased risk of skin cancer.

• Rinvoq Lawsuit Filed Against AbbVie By Investors Over Failure to Disclose Safety Concerns

  April 14, 2022

  Irvin Jackson

  AbbVie faces a class action lawsuit by investors who say the company mislead them about the safety of Rinvoq before new warning labels for cancer and heart problems were added.